ArticleBMC microbiology2025
Modulation of fibroblast behavior by Leishmania: a pathway to understanding disease progression in cutaneous leishmaniasis.
Article in BMC microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Phytol-loaded soybean oil nanoemulsion as a promising alternative againstBeilstein journal of nanotechnology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Leishmaniasis is a parasitic infection caused by obligatory intracellular protozoa of the Leishmania genus. Macrophages are the main cell for Leishmania parasites that play a key role in immune response against it. Interestingly, both the promastigote and amastigote forms of the parasite have also been detected in fibroblasts, revealing the complex interactions during the infection. Cutaneous leishmaniasis, caused by different Leishmania species, presents different clinical outcomes, largely influenced by the interactions between the parasite and host immune cells. This study aimed to determine how macrophages infected by Leishmania amazonensis or L. braziliensis, obtained from different clinical forms, modulate the response of dermal fibroblasts in an in vitro model. Our research shows that after 24 h; fibroblast migration was reduced by 1.5-fold with conditioned medium from L. braziliensis-infected macrophages. After 48 h, the G1-phase in fibroblasts was reduced by up to 54% compared to controls. Fibroblasts treated with L. amazonensis-infected macrophages showed a 75% decrease in MMP-2 activity at 24 h and 44% at 48 h, while L. braziliensis-treated fibroblasts showed a 24% decrease. IL-6 levels were significantly lower (91% for L. amazonensis and 84% for L. braziliensis) in fibroblasts after 24 h, with IL-6 increasing 1.6-fold in L. amazonensis-treated fibroblasts after 48 h. Correlation analysis showed that TNF-α levels were strongly negatively correlated with wound size, while IL-6 levels were negatively correlated with MMP-9 activity. These findings suggest that L. amazonensis promotes tissue repair through reduced MMP-2 activity and lower IL-6, whereas L. braziliensis enhances inflammation and extracellular matrix remodeling. In conclusion, this study highlights the pivotal role of fibroblasts as active participants in the immune response to Leishmania, with L. amazonensis promoting a more favorable environment for tissue repair and L. braziliensis promoting inflammation and tissue damage. This knowledge on host-Leishmania interactions could help improve knowledge of chronic or asymptomatic infections lead to more well-defined and efficient responses for controlling cutaneous leishmaniasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.